GCG and metabolic syndrome: In conclusion, this study highlights the effective role of combining GLP-1 and GIP/GLP-1 agonists with a continuous, digitally delivered behavioral change model by an integrated care team in managing MetS, particularly in reducing WC, improving lipid profiles, and enhancing glycemic control across different genders.